Cargando…
Simvastatin Inhibits CYR61 Expression in Orbital Fibroblasts in Graves' Ophthalmopathy through the Regulation of FoxO3a Signaling
Graves' ophthalmopathy (GO), which is characterized by orbital tissue inflammation, expansion, and fibrosis, is the ocular manifestation in 25% to 50% of patients with Graves' disease. As the pathology of GO is driven by autoimmune inflammation, many proinflammatory cytokines/chemokines, i...
Autores principales: | Wei, Yi-Hsuan, Liao, Shu-Lang, Wang, Chia-Chun, Wang, Sen-Hsu, Tang, Wan-Chun, Yang, Chang-Hao |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7843182/ https://www.ncbi.nlm.nih.gov/pubmed/33542676 http://dx.doi.org/10.1155/2021/8888913 |
Ejemplares similares
-
Simvastatin and ROCK Inhibitor Y-27632 Inhibit Myofibroblast Differentiation of Graves’ Ophthalmopathy-Derived Orbital Fibroblasts via RhoA-Mediated ERK and p38 Signaling Pathways
por: Wei, Yi-Hsuan, et al.
Publicado: (2021) -
Simvastatin downregulates adipogenesis in 3T3-L1 preadipocytes and orbital fibroblasts from Graves’ ophthalmopathy patients
por: Shahida, B, et al.
Publicado: (2019) -
Chitosan inhibits inflammation and adipogenesis of orbital fibroblasts in Graves ophthalmopathy
por: Xiong, Haibo, et al.
Publicado: (2018) -
Increased response to oxidative stress challenge in Graves’ ophthalmopathy orbital fibroblasts
por: Tsai, Chieh-Chih, et al.
Publicado: (2011) -
Imaging Evaluation of the Orbit in Graves Ophthalmopathy
por: SAS, T.N., et al.
Publicado: (2015)